OS Therapies Stock (NYSE:OSTX)

Forecast Ownership Financials Chart

Previous Close

$1.25

52W Range

$1.15 - $2.25

50D Avg

$1.60

200D Avg

$1.57

Market Cap

$58.51M

Avg Vol (3M)

$579.05K

Beta

-0.64

Div Yield

OSTX Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

Country

Employees

IPO Date

Aug 01, 2024

Website

OSTX Performance

OSTX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-28.71B	$-6.81M	$-4.34M
Net Income	$-28.75B	$-8.88M	$-7.79M
EBITDA	$-28.71B	$-6.83M	$-4.34M
Basic EPS	$-0.98	$-0.52	$-0.39
Diluted EPS	$-0.98	$-0.52	$-0.39

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
SPRB	Spruce Biosciences, Inc.
EQ	Equillium, Inc.
NRXP	NRx Pharmaceuticals, Inc.
OTLK	Outlook Therapeutics, Inc.
HOWL	Werewolf Therapeutics, Inc.
ADAG	Adagene Inc.
CRVO	CervoMed Inc.
INKT	MiNK Therapeutics, Inc.
IOBT	IO Biotech, Inc.